SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Cheeseburger who wrote (692)6/7/1999 5:06:00 PM
From: Invest2Ride  Read Replies (1) | Respond to of 900
 
Not only is the company past the "failure-ridden" stage of development, it has produced a tool rather than a narrowly focused drug product. This tool can be used to attack multiple fronts, each of which will generate their own revenue stream. This diverse application strength is evidenced by the two products that are coming to market, an anti-fungal treatment and an anti-cancer treatment.

Looking forward to the run...



To: Cheeseburger who wrote (692)6/7/1999 10:13:00 PM
From: Ed  Read Replies (1) | Respond to of 900
 
Two more positives:
Value Line has given it a 1
A biotech newsletter I get, Beck on Biotech, had it as one of it's
monthly picks. He had another one of my stocks, Enzon, as a monthly pick and it has done real well. I picked up some LIPO today. Between the two I am hopeful of big things.
Too


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News